PI3K/Akt/mTOR通路抑制剂依维莫司治疗晚期乳腺癌的研究进展  

Advances in inhibitors of PI3K/Akt/mTOR pathway in treatment of advanced breast cancer

作　　者：叶荆[1] 王蓓[2] 陈建彬[1] 高秀飞[2] 

机构地区：[1]浙江中医药大学第一临床医学院,浙江杭州310053 [2]浙江中医药大学附属第一医院乳腺科,浙江杭州310006

出　　处：《肿瘤》2015年第2期221-224,共4页Tumor

基　　金：2012年浙江省自然科学基金资助项目(编号:LY12H29004)~~

摘　　要：磷脂酰肌醇3-激酶/丝氨酸-苏氨酸蛋白激酶(phosphatidylinositol3-kinase/serine-threonine protein kinase,PI3K/Akt)信号通路活化是肿瘤细胞增殖、转移和抗凋亡的重要环节,已证实与乳腺癌芳香化酶抑制剂(aromatase inhibitors,AIs)抵抗以及曲妥珠单抗耐药有关。PI3K/Akt信号通路抑制剂联合AIs或人类表皮生长因子受体2(human epidermal growth factor receptor-2,HER2)靶向治疗在雌激素受体阳性晚期乳腺癌临床试验中显示出较好的有效性,能够显著改善患者的无进展生存时间,其中以PI3K/Akt/哺乳类动物雷帕霉素靶蛋白(mammalian target of rapamycin,m TOR)通路抑制剂依维莫司的研究及其临床应用最为成熟。本文对依维莫司在复发、转移和耐药乳腺癌治疗中的作用进行综述。The activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase （PI3K/Akt） signaling pathway plays an important role in cell proliferation, metastasis and apoptosis, and it has been proved to be associated with resistance to aromatase inhibitors （AIs） and trastuzumab in patients with breast cancer. The clinical trial of estrogen receptor-positive advanced breast cancer has revealed that the targted therapy of inhibitors of PI3K/Akt signaling pathway in combination with AIs/human epidermal growth factor receptor-2 （HER2） could achieve a good response and improve the progression-free survival. The study and clinical application of everolimus, an inhibitor of PI3K/Akt/ mammalian target of rapamycin （mTOR） signaling pathway, are most ripe. This review focuses on the advances in the role of everolimus in the treatment of recurrent, metastatic and resistant breast cancer.

关 键 词：乳腺肿瘤 芳香化酶抑制剂抵抗 曲妥珠单抗耐药 依维莫司 

分 类 号：R737.9[医药卫生—肿瘤]